Intetumumab

Research use only, not for human use.

Intetumumab (CNTO 95) is a fully human anti-α(v)-integrin monoclonal antibody that is a radiosensitizer in xenograft tumor-bearing mice, inhibits tumor growth, and reduces lung metastases in the A549 NSCLC xenograft model.

Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer.

Intetumumab (CNTO 95; 0-5 μg/mL; 20 min; USPC-ARK-3 cells) inhibits integrin-mediated USPC cell adherence to a vitronectin substratum and inhibits serum-induced migration of USPC cells.

Intetumumab (CNTO 95; 10 mg/kg; i.p.; Male nude rats) inhibits tumor growth and inhibits spontaneous lung metastasis of A549 tumors and decreases both the number of rats with lung metastasis and the number of metastatic lesions per lung.Animal Model:Male nude rats with lung metastasis models (5-6 weeks old and 150-200 g)Dosage:10 mg/kg Administration:Intraperitoneal injection; once a week for 60 days Result:Had the total tumor response rates (CR and PR) was 33% in A549 tumor model.Developed lung metastases only 4 of 9 rats.

——

Angiogenesis

EGFR

EGFR

——

——

725735-28-4

145.6 (kDa)

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years